Efficacy

Polivy (polatuzumab vedotin-piiq) for Lymphoma

Polivy (polatuzumab vedotin-piiq) is a targeted cancer medicine that is used in combination with other drugs to treat diffuse large B-cell lymphoma (DLBCL), which is the most common type of non-Hodgkin lymphoma in adults. Specifically, Polivy is indicated for patients who have relapsed or refractory DLBCL after at least two prior therapies. The efficacy of Polivy was demonstrated in a pivotal clinical trial, which showed that the combination of Polivy with bendamustine and rituximab (BR) significantly improved response rates and survival outcomes compared to BR alone. Patients receiving the Polivy combination had a higher complete response rate, meaning that no cancer could be detected after treatment.

In the study, the median progression-free survival, which is the time during and after treatment that a patient lives with the disease without it getting worse, was significantly longer for patients treated with the Polivy combination compared to those who received BR alone. This suggests that Polivy can offer a valuable treatment option for patients with relapsed or refractory DLBCL, potentially extending the time they can live without disease progression.

Jaypirca (pirtobrutinib) for Lymphoma

Jaypirca (pirtobrutinib) is an investigational, highly selective, non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, which is being studied for the treatment of various B-cell malignancies, including lymphoma. While Jaypirca is not yet approved, clinical trials have been conducted to assess its efficacy in patients with B-cell malignancies, such as mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and other lymphomas that have progressed after previous therapies. The results from early-phase trials have shown promising efficacy, with a significant proportion of patients achieving partial or complete responses to the treatment.

One of the key advantages of Jaypirca is its ability to overcome resistance to other BTK inhibitors due to its non-covalent binding mechanism. This has been particularly important for patients who have developed resistance to covalent BTK inhibitors, as Jaypirca provides a potential new line of therapy. The ongoing clinical trials continue to evaluate the efficacy and safety profile of Jaypirca in larger patient populations and across different types of lymphomas. As research progresses, Jaypirca may become an important addition to the therapeutic arsenal against B-cell lymphomas, particularly for patients who have limited treatment options due to resistance or intolerance to current therapies.